Table of Contents: 2017 NOVEMBER - DECEMBER No. 419
RxNorm December 2017 Release. NLM Tech Bull. 2017 Nov-Dec;(419):b8.
The RxNorm December 2017 full monthly release is available as of Monday, December 4, 2017. The United States Food and Drug Administration (FDA) started adding 4-letter suffixes to the nonproprietary ingredient name of new biological products. The FDA-designated distinguishing suffix is devoid of meaning and composed of four lowercase letters.
RxNorm is representing the nonproprietary ingredient name lacking the 4-letter suffix as an ingredient (TTY=IN). The more granular ingredient name with the 4-letter suffix is represented as a precise ingredient (TTY=PIN).
To illustrate, here are several RxNorm forms for the biological product Renflexis:
| TTY | RXCUI | String |
| SBD | 1927290 | infliximab-abda 100 MG Injection [Renflexis] |
| SCD | 1927285 | infliximab-abda 100 MG Injection |
| PIN | 1927283 | infliximab-abda |
| IN | 191831 | infliximab |
For more information, see Nonproprietary Naming of Biological Products: Guidance for Industry (PDF format) from the FDA.
